Allergic rhinitis (AR) has become a global health problem that constantly affects a large part of the general population, especially children.
Objective
Sublingual allergen immunotherapy (SLIT) has been used extensively for pediatric AR, although its efficacy and safety are often questioned. In this meta-analysis of randomized controlled trials (RCT), we evaluated the use of SLIT for pediatric AR.
Methods
A number of medical literature data bases were searched through January 2016 to identify RCTs that examined the use of SLIT for pediatric AR and that assessed clinical outcomes related to efficacy. Descriptive and quantitative information was abstracted. Standardized mean differences (SMD) were calculated by using fixed- and random-effects models. Subgroup analyses were performed. Heterogeneity was assessed by using the I2metric. A network meta-analysis was used to estimate SMDs between two SLIT protocols for pediatric seasonal AR. All data were extracted from publications or received from the authors.
Results
Twenty-six studies were eligible for inclusion in the meta-analysis of rhinitis or rhinoconjunctivitis symptom scores, and 19 studies were eligible for the meta-analysis of medication scores. Descriptive and quantitative data were extracted. SLIT differed significantly from placebo in terms of symptom scores (SMD -0.55 [95% confidence interval {CI}, -0.86 to -0.25]; p = 0.0003, I2 = 90%) and medication scores (SMD -0.67 [95% CI, -0.96 to -0.38J; p < 0.00001, I2 = 83%). Oral pruritus was the adverse effect, which occurred most commonly in children who were receiving SLIT. Network meta-analysis revealed no significant difference between the pre-coseasonal and continuous SLIT protocols for seasonal AR in symptom scores (SMD -6.55 [95% CI, -25.38 to 12.29]; p = 0.496) and medication scores (SMD -8.83 [95% CI, -22.10 to 4.43]; p = 0.192).
Conclusions
Our meta-analysis results indicated that SLIT provided significant symptom relief and reduced the need for medication in pediatric patients Moreover, the safety of SLIT needs to be confirmed in RCTs with larger samples.
Get full access to this article
View all access options for this article.
References
1.
MeltzerE.O., BlaissM.S., DereberyM.J.Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey.J Allergy Clin Immunol124(suppl.): S43–S70, 2009.
2.
BauchauV., and DurhamS.R.Prevalence and rate of diagnosis of allergic rhinitis in Europe.Eur Respir J24: 758–764, 2004.
3.
SchwindtC.D., and SettipaneR.Allergic rhinitis (AR) is now estimated to affect some 1.4 billion people globally and continues to be on the rise. Editorial.Am J Rhinol Allergy26(suppl 1): S1, 2012.
4.
MeltzerE.O., BlaissM.S., NaclerioR.M.Burden of allergic rhinitis: Allergies in America, Latin America, and Asia-Pacific adult surveys.Allergy Asthma Proc33(suppl 1): S113–S141, 2012.
5.
MeltzerE.O.Quality of life in adults and children with allergic rhinitis.J Allergy Clin Immunol108(suppl.): S45–S53, 2001.
6.
LegerD., Annesi-MaesanoI., CaratF.Allergic rhinitis and its consequences on quality of sleep: An unexplored area.Arch Int Med166: 1744–1748, 2006.
7.
HankinC.S., CoxL., LangD.Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: A large-scale, retrospective, matched cohort study.Ann Allergy Asthma Immunol104: 79–85, 2010.
8.
WallaceD.V., DykewiczM.S., BernsteinD.I.The diagnosis and management of rhinitis: An updated practice parameter.J Allergy Clin Immunol122(suppl.): S1–S84, 2008.
9.
CalderonM.A., DemolyP., Gerth van WijkR.EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.Clin Transl Allergy2: 20, 2012.
10.
MeltzerE.O., and BuksteinD.A.The economic impact of allergic rhinitis and current guidelines for treatment.Ann Allergy Asthma Immunol106(suppl.): S12–S16, 2011.
11.
BurksA.W., CalderonM.A., CasaleT.Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/ European Academy of Allergy and Clinical Immunology/PRACTALL consensus report.J Allergy Clin Immunol131: 1288–1296.e3, 2013.
12.
BrozekJ.L., BousquetJ., Baena-CagnaniC.E.Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.J Allergy Clin Immunol126: 466–476, 2010.
13.
BousquetJ., KhaltaevN., CruzA.A.Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).Allergy63(suppl 86): 8–160, 2008.
14.
MorjariaJ.B., CarusoM., RosaliaE.Preventing progression of allergic rhinitis to asthma.Curr Allergy Asthma Rep14: 412, 2014.
15.
LeeS., NolteH., and BenningerM.S.Clinical considerations in the use of sublingual immunotherapy for allergic rhinitis.Am J Rhinol Allergy29: 106–114, 2015.
16.
TabatabaianF., and CasaleT.B.Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT).Allergy Asthma Proc36: 100–104, 2015.
17.
CoxL.Sublingual immunotherapy for aeroallergens: Status in the United States.Allergy Asthma Proc35: 34–42, 2014.
18.
CalderonM.A., BirkA.O., AndersenJ.S., and DurhamS.R.Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy.Allergy62: 958–961, 2007.
19.
DurhamS.R., YangW.H., PedersenM.R.Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis.J Allergy Clin Immunol117: 802–809, 2006.
20.
PassalacquaG., and CanonicaG.Sublingual or injection immunotherapy: The final answer?Allergy59: 37–38, 2004.
21.
PenagosM., PassalacquaG., CompalatiE.Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age.Chest133: 599–609, 2008.
22.
PassalacquaG., CompalatiE., and CanonicaG.W.Sublingual Immunotherapy: Clinical indications in the WAO-SLIT Position Paper.World Allergy Organ J3: 216–219, 2010.
23.
RobertsG., XatzipsaltiM., BorregoL.M.Paediatric rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology.Allergy68: 1102–1116, 2013.
24.
Di BonaD., PlaiaA., Leto-BaroneM.S.Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: A systematic review and meta-analysis.JAMA Intern Med175: 1301–1309, 2015.
PenagosM., CompalatiE., TarantiniF.Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: A meta-analysis of randomized, placebo-controlled, double-blind trials.Ann Allergy Asthma Immunol97: 141–148, 2006.
27.
WilsonD.R., LimaM.T., and DurhamS.R.Sublingual immunotherapy for allergic rhinitis: Systematic review and meta-analysis.Allergy60: 4–12, 2005.
28.
CompalatiE., PassalacquaG., BoniniM., and CanonicaG.W.The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: Results of a GA2LEN meta-analysis.Allergy64: 1570–1579, 2009.
29.
AydoganM., EifanA.O., KelesS.Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: A double-blind-placebo-controlled randomised trial.Respir Med107: 1322–1329, 2013.
30.
BahçecilerN.N., IsikU., BarlanI.B., and BasaranM.M.Efficacy of sublingual immunotherapy in children with asthma and rhinitis: A doubleblind, placebo-controlled study.Pediatr Pulmonol32: 49–55, 2001.
31.
IppolitiF., De SantisW., VolterraniA.Immunomodulation during sublingual therapy in allergic children.Pediatr Allergy Immunol14: 216–221, 2003.
32.
HirschT., SahnM., and LeupoldW.Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children.Pediatr Allergy Immunol8: 21–27, 1997.
33.
de BotC.M., MoedH., BergerM.Y.Sublingual immunotherapy not effective in house dust mite-allergic children in primary care.Pediatr Allergy Immunol23: 150–158, 2012.
34.
WüthrichB., BucherCh, JorgW.Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen.J Investig Allergol Clin Immunol13: 145–148, 2003.
35.
WahnU., TabarA., KunaP.Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.J Allergy Clin Immunol123: 160–166.e3, 2009.
36.
RöderE., BergerM.Y., HopW.C.Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care.J Allergy Clin Immunol119: 892–898, 2007.
37.
La RosaM., RannoC., AndreC.Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis.J Allergy Clin Immunol104: 425–432, 1999.
38.
BufeA., EberleP., Franke-BeckmannE.Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.J Allergy Clin Immunol123: 167–173.e7, 2009.
39.
BlaissM., MaloneyJ., NolteH.Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents.J Allergy Clin Immunol127: 64–71, 71.e1-e4, 2011.
40.
AhmadiafsharA., MaarefvandM., TaymourzadeB.Efficacy of sublingual swallow immunotherapy in children with rye grass pollen allergic rhinitis: A double-blind placebo-controlled study.Iran J Allergy Asthma Immunol11: 175–181, 2012.
41.
YukselenA., KendirliS.G., YilmazM.Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: A randomized, placebo-controlled, double-blind, double-dummy study.Int Arch Allergy Immunol157: 288–298, 2012.
42.
StelmachI., Kaczmarek-WozniakJ., MajakP.Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.Clin Exp Allergy39: 401–408, 2009.
43.
TsengS.H., FuL.S., NongB.R.Changes in serum specific IgG4 and IgG4/IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: A multicenter, randomized, placebo-controlled trial.Asian Pac J Allergy Immunol26: 105–112, 2008.
44.
ShaoJ., CuiY.X., ZhengY.F.Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis.Am J Rhinol Allergy28: 131–139, 2014.
45.
VourdasD., SyrigouE., PotamianouP.Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization.Allergy53: 662–672, 1998.
46.
ValovirtaE., JacobsenL., LjorringC.Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.Allergy61: 1177–1183, 2006.
47.
StelmachI., Kaluzinska-ParzyszekI., JerzynskaJ.Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children.Allergy67: 312–320, 2012.
48.
Rolinck-WerninghausC., WolfH., LiebkeC.A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.Allergy59: 1285–1293, 2004.
49.
CaffarelliC., SensiL.G., MarcucciF., and CavagniG.Preseasonal local allergoid immunotherapy to grass pollen in children: A double-blind, placebo-controlled, randomized trial.Allergy55: 1142–1147, 2000.
50.
BufeA., Ziegler-KirbachE., StoeckmannE.Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: A double-blind placebo-controlled study.Allergy59: 498–504, 2004.
51.
YonekuraS., OkamotoY., SakuraiD.Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children.Allergol Int59: 381–388, 2010.
52.
TariM.G., MancinoM., and MontiG.Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study.Allergol Immunopathol (Madr)18: 277–284, 1990.
53.
EifanA.O., AkkocT., YildizA.Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: An open randomized controlled trial.Clin Exp Allergy40: 922–932, 2010.
54.
MarcucciF., SensiL., FratiF.Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites.Allergy58: 657–662, 2003.
55.
KimJ.M., LinS.Y., Suarez-CuervoC.Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: A systematic review.Pediatrics131: 1155–1167, 2013.
AssanasenP., BaroodyF.M., NaureckasE., and NaclerioR.M.Warming of feet elevates nasal mucosal surface temperature and reduces the early response to nasal challenge with allergen.J Allergy Clin Immunol104: 285–293, 1999.
58.
WangK.Y., and ChauT.T.An association between air pollution and daily outpatient visits for respiratory disease in a heavy industry area.PLoS One8: e75220, 2013.
59.
PLOS Medicine Staff.Correction: Active or passive exposure to tobacco smoking and allergic rhinitis, allergic dermatitis, and food allergy in adults and children: A systematic review and meta-analysis.PLoS Med13: e1001939, 2016.
CochardM.M., and EigenmannP.A.Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy.J Allergy Clin Immunol124: 378–379, 2009.
62.
RienzoV.D., MinelliM., MusarraA.Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years.Clin Exp Allergy35: 560–564, 2005.
63.
FiocchiA., PajnoG., La GruttaS.Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years.Ann Allergy Asthma Immunol95: 254–258, 2005.
